View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordis...

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 20 February 2026 – The Annual General Meeting will be held on: Thursday 26 March 2026 at 14:00 (CET) The Annual General Meeting will be held as a combined physical and virtual meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, entrance 6, 2300 Copenhagen S, Denmark, or virtually by PC or smartphone/tablet. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual Gen...

Chaima Ferrandon ... (+2)
  • Chaima Ferrandon
  • Sven Edelfelt
Chaima Ferrandon ... (+2)
  • Chaima Ferrandon
  • Sven Edelfelt
 PRESS RELEASE

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will rep...

Stephane Foucaud
  • Stephane Foucaud

AUCTUS ON FRIDAY - 13.02.2026

AUCTUS PUBLICATIONS ________________________________________ Criterium Energy (CEQ CN)C; Target price of C$0.35 per share: First Gas in 2Q26 with a Likely Upgrade to Discovered Gas Resources – The contract for the construction of a new 21 km gas pipeline (previously 14 km) for the SE‑MGH 5–7 mmcf/d development was signed in early January. Site preparation is already underway, with first gas expected in 2Q26. Project capex is now estimated at US$2 mm (vs. prior guidance of US$2–3 mm), of which US...

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 11 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of ...

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 10 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of ...

 PRESS RELEASE

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 9 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will repu...

 PRESS RELEASE

Novo Nordisk takes legal action against Hims & Hers to protect patient...

Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic® Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at riskNovo Nordisk takes decisive legal action to stop Hims’ illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetesNovo Nordisk is asking the court to permanently ban Hims from selling unappr...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch